Funding Opportunity ID: |
321019 |
Opportunity Number: |
RFA-DK-19-504 |
Opportunity Title: |
Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional) |
Opportunity Category: |
Discretionary |
Opportunity Category Explanation: |
|
Funding Instrument Type: |
Cooperative Agreement |
Category of Funding Activity: |
Education Food and Nutrition Health |
Category Explanation: |
|
CFDA Number(s): |
93.393 93.399 93.847 |
Eligible Applicants: |
Public and State controlled institutions of higher education |
Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding announcement for the eligibility details |
Agency Code: |
HHS-NIH11 |
Agency Name: |
Department of Health and Human Services National Institutes of Health |
Posted Date: |
Sep 26, 2019 |
Close Date: |
Dec 17, 2019 |
Last Updated Date: |
Sep 26, 2019 |
Award Ceiling: |
$0 |
Award Floor: |
$0 |
Estimated Total Program Funding: |
|
Expected Number of Awards: |
|
Description: |
This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-19-009 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html). |
Version: |
1 |